Merck presents data from new Phase 3 trials to treat mCRPC patients
Category: #health  By Mateen Dalal  Date: 2019-02-16
  • share
  • Twitter
  • Facebook
  • LinkedIn

Merck presents data from new Phase 3 trials to treat mCRPC patients

Pharmaceutical major Merck & Co Inc., has apparently announced the launch of three late-stage studies for KEYTRUDA – its cancer immunotherapy. Trusted reports cite that these studies are being introduced as a combination treatment for the much-dreaded prostate cancer after the supposed drug depicted anti-tumor activity in an early-stage trial.

As per sources familiar with the knowledge of the matter, the findings of the Phase 1b/2 KEYNOTE-365 trial, investigating Merck’s anti-PD-1 therapy KEYTRUDA, in combination with myriad agents for treating patients suffering from mCRPC (metastatic castration-resistant prostate cancer), depicted anti-tumor activity across three study cohorts. One of these cohorts investigated KEYTRUDA in combination with LYNPARZA, the second cohort investigated KEYTRUDA in combination with docetaxel and prednisone, while the third cohort did so in conjunction with enzalutamide.

For the record, these results were presented at the 2019 ASCO GU (Genitourinary Cancers Symposium) in San Francisco.

According to an official press release by the company, Dr. Roy Baynes, Senior VP & chief medical officer, Merck, was quoted stating that at the very epicenter of the firm’s research program lies its commitment to investigate the massive potential of KEYTRUDA as a monotherapy and as a combination therapy to cater to the requirement of fundamental treatment in cancers that demand the deployment of additional therapies. The data presented at ASCO GU in conjunction with the unmet medical needs in patients with mCRPC encouraged the firm to initiate three new Phase 3 trials to analyze the KEYTRUDA combination regimens, Baynes added.

Incidentally, Merck’s current clinical development program in metastatic prostate cancer is inclusive of studies that evaluate KEYTRUDA and LYNPARZA as a monotherapy and in combination with anti-cancer therapies with other mechanisms of action. The present trials in existence include the Phase 3 trials PROfound analyzing LYNPARZA monotherapy in collaboration with AstraZeneca, PROPEL analyzing LYNPARZA in combination with abiraterone (as a first-line therapy) in mCRPC patients, and the Phase 2 KEYNOTE-199 trial for KEYTRUDA monotherapy.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Ather Energy raises $250 million to stay ahead in competition
Ather Energy raises $250 million to stay ahead in competition
By Mateen Dalal

Electric scooter producer Ather Energy has reportedly secured $250 million in a new funding round. As per reports, the investment round is in its early stages. The company’s goal is to obtain $200 million to $250 million to compete in the EV...

Digital wellness startup Mojorcare bags USD 20 Mn in Series A funding
Digital wellness startup Mojorcare bags USD 20 Mn in Series A funding
By Mateen Dalal

Mojocare, a wellness and health startup has reportedly raised USD 20.6 million in a Series A round of funding which was led by B Capital Group and saw participation from existing investors including Sequoia India’s Surge, Better Capital, and Ch...

Exponent Energy bags USD 13 million in Lightspeed-led Series A funding
Exponent Energy bags USD 13 million in Lightspeed-led Series A funding
By Mateen Dalal

Bangalore-based Exponent Energy has reportedly secured USD 13 million in a Series A funding round which was spearheaded by Lightspeed Venture Partners. The round also saw participation from existing investors such as 3one4 Capital, YourNest VC, and A...